The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…

Subcategories:Axial SpondyloarthritisClinical Criteria/GuidelinesGout and Crystalline ArthritisMyositisOsteoarthritis and Bone DisordersOther Rheumatic ConditionsPain SyndromesPediatric ConditionsPsoriatic ArthritisRheumatoid ArthritisSjögren’s DiseaseSoft Tissue PainSystemic Lupus ErythematosusSystemic SclerosisVasculitis

The FDA has approved abatacept to treat adults with active psoriatic arthritis. In clinical trials, the treatment has proved effective in both intravenous and subcutaneous forms…

Research has shed light on the genetic mutations that link GDF5 with arthritis and height. An ancient regulatory variant in GROW1 has been repeatedly selected in humans in northern environments, explaining the high frequency of a GDF5 haplotype that increases arthritis susceptibility…
Reuters Staff |
NEW YORK (Reuters Health)—Advice is considered an effective treatment for acute low back pain (LBP), but neither clinical trials nor guidelines include adequate detail on what this advice should be, or how doctors should deliver it, according to a new review. And half of the advice topics included in guidelines were discordant with evidence from…
A new guideline developed by the ACR and the American Association of Hip and Knee Surgeons addresses the perioperative use of antirheumatic drug therapy. Specifically, it provides recommendations on the use of traditional disease-modifying antirheumatic drugs, biologic agents, tofacitinib and glucocorticoids in adults with RA; SpA, including ankylosing spondylitis and psoriatic arthritis; JIA; or SLE undergoing elective THA or TKA. The guideline provides recommendations regarding when to continue, when to withhold and when to restart these medications, and the optimal perioperative dosing of glucocorticoids…

Researchers may have established a relationship between a new RA autoantibody, anti-carbamylated protein (anti-CarP) antibodies, and increased mortality risk. The recent study showed that anti-CarP was the only autoantibody associated with mortality, specifically respiratory system cause of death…
Will Boggs MD |
(Reuters Health)—Participation in some sports, including soccer, wrestling and elite-level long-distance running, may increase the risk of knee osteoarthritis, researchers say. “While the typical athlete is not at a greater risk of knee osteoarthritis, it was interesting to see that certain athletes may be more likely to have knee osteoarthritis later in life, specifically, elite…

Romosozumab’s Future Is Uncertain Romosozumab, which has the possible U.S. brand name Evenity, is awaiting approval from the FDA.1 The treatment is an investigational, injectable biologic for treating osteoporosis. It increases bone formation and bone density, reducing a patient’s risk of fractures. The manufacturer no longer expects the FDA to approve the drug this year…
Reuters Staff |
NEW YORK (Reuters Health)—The renal protective effect of allopurinol appears to differ from that of febuxostat in the elderly, according to new research. The study, of a nationally representative sample of Medicare patients, showed that allopurinol was associated with a greater reduction in the risk of incident kidney disease, report the authors online July 13…
David Douglas |
NEW YORK (Reuters Health)—Early immune response signatures in the critically injured may shed light on mechanisms underlying multiple organ system failure, according to U.K. investigators. As Dr. Joanna M. Shepherd of Queen Mary University of London tells Reuters Health by email, “Multiple organ dysfunction syndrome (MODS) is common after major trauma and it contributes to…

Although rituximab is not indicated for adults with SLE, a recent review suggests that it may be safe and effective for treating pediatric SLE. The review found that rituximab improved renal function and reduced proteinuria in pediatric patients. It may also prevent relapse and improve disease activity…